Back to top

Analyst Blog

Impax Laboratories, Inc. (IPXL - Snapshot Report) recently announced that the US Food and Drug Administration (FDA) completed its re-inspection of the company’s manufacturing facility at Hayward.  

The re-inspection was undertaken due to a previously disclosed Form 483 issued in Mar 2012.

Additionally, the FDA conducted a Pre-Approval Inspection (PAI) for candidate Rytary in order to validate the analytical method undertaken. Rytary is being developed for the symptomatic treatment of Parkinson’s disease.

Further, the FDA also conducted a general Good Manufacturing Practices (GMP) inspection and observed deviations from the current practices by Impax.

We note that Impax has been hampered by quality control issues since 2011. In May 2011, Impax received a warning letter from the FDA after an inspection of the company’s facility at Hayward. The inspection was conducted between Dec 13, 2010 and Jan 21, 2011.

Subsequently, Impax responded to the warning letter and received an acknowledgement letter for a complete response from the FDA in Dec 2011.

Thereafter, in 2012, the FDA completed a re-inspection of the concerned facility along with a general GMP inspection and issued Form 483 with its observations. A satisfactory re-inspection by the FDA is mandatory to close the warning letter.

However, the outcome of the re-inspection was not positive for Impax. After the latest inspection, the FDA has issued a new Form 483 with 12 observations. Out of these12, 3 are repeat observations from inspections that occurred prior to the warning letter. 

Impax expects to respond to these new observations within 15 business days from the receipt of Form 483. The news impacted the stock negatively.

Impax is working diligently on the issues noted by the FDA and expects to resolve the matter quickly. However, the new Form 483 remains a major overhang on the stock.

Impax currently carries a Zacks Rank #4 (Sell). Right now, Mylan (MYL - Analyst Report), Pernix Therapeutics and Avanir Pharmaceuticals (AVNR - Snapshot Report) look well placed in the pharma space. All three stocks carry a Zacks Rank #2 (Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SUPER MICRO… SMCI 26.63 +8.74%
CENTURY ALU… CENX 27.09 +8.45%
BANCO DO BR… BDORY 16.55 +6.57%
CANADIAN SO… CSIQ 37.50 +5.81%
GTT COMMUNI… GTT 12.86 +5.07%